Call us toll free: (317)727-9173
Top notch Multipurpose WordPress Theme!

FDA’s New NDI Guidance is Progress, But Big Questions Still Unresolved

FDA’s New NDI Guidance is Progress, But Big Questions Still Unresolved

FDA’s new NDI guidance is progress, but it still leaves some of the industry’s most fundamental regulatory questions unresolved.

Whats the difference between a food and a dietary supplement? And what should we do with ingredients which could potentially be used in both supplements and foods?

In the U.S., a beverage, gummy, or powder could be marketed as either. The physical form doesn’t tell us what it is. In fact, whether a product has a Nutrition Facts Panel or a Supplement Facts Panel is often left up to a Rube Goldbergian type of decision process.

Sure, “food” and “dietary supplement” are regulatory classifications, shaped by decades of U.S. law. Yet the classifications can lead to very different requirements for the same ingredient.

The pathways aren’t interchangeable per the regs, yet the overlap between them is considerably large and blurry.

After more than 30 years of DSHEA, we need a more coherent framework connecting GRAS and NDI requirements.

—-

Heres what it advances:

Identity: More detailed expectations for specifications and composition

History of safe use: Greater clarity on documenting exposure, including a general benchmark of 25 years of widespread use.

Scientific evidence: Recognition that relevant safety data from comparable ingredients and test materials may support a safety conclusion.

Toxicology: More explicit recommendations for selecting studies and calculating margins of safety.

Modern methods: recognition of new approaches, including in vitro and computational approaches, as potentially useful.

Microbials: Detailed recommendations on strain identity, toxins and antibiotic resistance.

Much of this builds on recommendations first proposed in 2016, and seems self-evident to anyone steeped in the science.

While guidance is not regulation, finalizing these sections provides a clearer basis for preparing and evaluating NDINs.

Now, what are we still waiting for?

—

FDA NDI Guidance Reference 2026

Some of the biggest questions concern the boundaries of the NDI framework itself:

GRAS versus NDI: When does conventional food use exempt an ingredient from an NDIN, and how should the two safety frameworks interact?

Ingredient eligibility: Which synthetic, biosynthesized, or novel substances qualify as dietary ingredients?

Chemical alteration: When does extraction, purification, fermentation, or other processing create a materially different ingredient?

Grandfathered status: What evidence adequately establishes pre-1994 marketing?

Master files: How can suppliers efficiently support multiple customers using shared safety data?

These are essential questions.

FDA has made progress explaining what should be part of an NDI.

But we’re still waiting for greater clarity on the bigger picture items, including how these regulatory pathways should fit together.

This will surely be hot topic of discussion at SupplySide Global.

About the Author:

Sorry, the comment form is closed at this time.